Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Universal Ibogaine has appointed Nick Karos as CEO on an interim basis, effective immediately.
  • Mr. Karos is a seasoned financier whose career has included senior roles with several US investment banks
  • Mr. Karos remains a short-listed candidate for the permanent position
  • Universal Ibogaine is a life sciences company researching medicalized ibogaine-centred addiction care
  • Universal Ibogaine Inc. (IBO) opened trading at C$0.14 per share

Universal Ibogaine (IBO) has appointed Nick Karos as CEO on an interim basis, effective immediately. 

Mr. Karos is based in Los Angeles, USA, and is a seasoned financier. His career includes senior roles with several US investment banks and most recently as CEO of Private Trading Group, which has provided business development and capital raising services for several successful start-up ventures.

Nick Karos sat down with Caroline Egan to discuss the appointment.

“I’m very excited to work with the talented partners at UI to move towards our goal of conducting clinical trials with Health Canada. Universal Ibogaine’s goal is to transform the addiction treatment model using ibogaine as the cornerstone of our new addiction treatment protocol. Addiction is a disease that affects society like none other, and we believe our ground-breaking protocol will give patients and families a better path towards long-term recovery.”

The board will immediately begin an executive search process for selecting a new CEO. Mr. Karos remains a short-listed candidate for the permanent position.

Universal Ibogaine is a life sciences company with a mission to research and deliver medicalized ibogaine-centred addiction care.

Universal Ibogaine Inc. (IBO) opened trading at C$0.14 per share.

More From The Market Herald

@ the Bell: TSX attempts rebound after worst day in a year

Support from higher commodity prices helped keep the TSX in the green for much of Friday … until markets closed.

How this company’s Georgia lithium plant will revolutionize the industry

Lithium-ion iron phosphate batteries are gaining traction in North America, and Full Circle Lithium is at the epicentre of the revolution.  

Arch Biopartners applies to test its kidney injury prevention drug

Arch Biopartners (TSXV:ARCH) is gearing up for a Phase II trial in Turkey for its lead drug candidate LSALT peptide.

The massive potential of the Baptiste Nickel Project’s impact

It’s been a busy start of the year for FPX Nickel (TSXV:FPX) thanks to some recent developments that will have investors paying attention.